UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2163-10
Program Prior Authorization/Medical Necessity - Devices
Medication Alevicyn*, Alevicyn Dermal Spray*, Alevicyn SG*, Aquoral*,
Atopaderm*, Atopiclair*, Atrapro Antipruritic Hydrogel*, Atrapro
CP*, Atrapro Dermal Spray*, Caphosol*, Ceracade*, Ceramax*,
Derpixa*, Dexeryl*, Eletone*, Emulsion SB*, Entty Spray*,
EpiCeram*, Halucort*, HPR*, HPRPlus*, Hyclodex*, Hylaguard,
Hylatopic Plus*, Hypocyn Dermal Spray*, Iliderm*, KamDoy Rx*,
Kendall Amorphous Hydrogel*, Keragel*, Keragelt*, Kivik*,
MediHoney*, Microcyn*, Neocera*, Neosalus*, NeutraSal*,
Nutraseb*, Penlen*, Phlag*, PR Cream*, Presera*, Promiseb*,
Pruclair*, Prumyx*, RadiaPlexRx*, SalivaMax*, Strata GRT*,
Suvicort*, Synerderm*, Tetrix*, Vexasyn*, Zanabin*
P&T Approval Date 4/2019, 7/2019, 4/2020, 8/2020, 12/2020, 2/2021, 8/2021, 9/2022,
11/2023, 11/2024
Effective Date 2/1/2025
1. Background:
The U.S. Food and Drug Administration (FDA) classifies devices as products that are intended
for use in the diagnosis, cure, mitigation, treatment, or prevention of a disease that do not
achieve their purpose through chemical action and are not dependent on metabolism to achieve
their purpose. Devices are typically benefit exclusions. This program only applies when devices
are covered by the plan.
2. Coverage Criteriaa:
A. Initial Therapy
1. Alevicyn*, Alevicyn SG*, Atopaderm*, Atopiclair*, Atrapro Antipruritic
Hydrogel*, Atrapro CP*, Ceracade*, Ceramax*, Dexeryl*, Eletone*, Emulsion
SB*, Entty Spray*, EpiCeram*, Halucort*, HPR*, HPRPlus*, Hylaguard,
Hylatopic Plus*, Iliderm*, KamDoy Rx*, Kivik*, Neocera*, Neosalus*,
Nutraseb*, Penlen*, Phlag*, PR Cream*, Presera*,Promiseb*, Pruclair*,
Prumyx*, Synerderm*, Tetrix*, and Zanabin* will be approved based on all of the
following criteria:
a. Diagnosis of one of the following:
(1) atopic dermatitis
(2) allergic contact dermatitis
(3) radiation dermatitis
(4) seborrheic dermatitis
-AND-
b. History of failure or contraindication to two OTC emollients (e.g. Aquaphor,
© 2024 UnitedHealthcare Services, Inc.
1
Eucerin, Lubriderm, white petroleum; document name and duration of trial)
-AND-
c. History of failure or contraindication to two topical corticosteroids. Document
topical corticosteroid name and duration of trial
Authorization will be issued for 12 months
2. Aquoral*, Caphosol*, NeutraSal* and SalivaMax* will be approved based on one
of the following criteria:
a. Both of the following:
(1) Diagnosis of xerostomia
-AND-
(2) History of failure or contraindication to both of the following:
(a) saliva stimulants (e.g. sugar-free hard candies or gum)
-AND-
(b) Two OTC saliva substitutes (e.g. Biotene, Mouth Kote, Oasis, SalivaSure,
Salivea) Document name and duration of trial
-OR-
b. Both of the following:
(1) Diagnosis of oral mucositis
-AND-
(2) History of failure or contraindication to both of the following:
(a) topical lidocaine
(b) salt and sodium bicarbonate rinse
Authorization will be issued for 12 months
3. Alevicyn Dermal Spray*, Atrapro Dermal Spray*, Hyclodex*, Hypocyn Dermal
Spray* and Microcyn* will be approved based on the following criteria:
a. History of failure or contraindication to two OTC antiseptics (e.g. Betadine,
Dakin’s Solution, Hibiclens). Document name and duration of trial
Authorization will be issued for 12 months
© 2024 UnitedHealthcare Services, Inc.
2
4. Derpixa*, Kendall Amorphous Hydrogel*, Keragel*, Keragelt*, MediHoney*,
RadiaPlexRx*, Strata GRT*, Vexasyn* and Suvicort* will be approved based on
the following criteria:
a. History of failure or contraindication to two OTC emollients (e.g. Aquaphor,
Eucerin, Lubriderm, white petroleum; document name and duration of trial)
Authorization will be issued for 12 months
B. Reauthorization
1. The requested device will be approved based on the following criteria:
a. Documentation of a positive response to therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Devices are typically excluded from coverage.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
4. References:
1. U.S. Food and Drug Administration. Classify Your Medical Device. Last updated 2/7/2020.
Retrieved from https://www.fda.gov/medical-devices/overview-device-
regulation/classify-your-medical-device. Accessed October 4, 2024.
2. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al.
Guidelines of care for the management of atopic dermatitis: section 2. Management and
treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014
Jul;71(1):116-32.
3. Fonacier L, Bernstein D, Pacheco K, et al. Atopic dermatitis: A practice parameter update
2015. J Allergy Clin Immunol 2015;3:S1-S39.
4. McGuire D, Fulton J, Park J, et al. Systematic review of basic oral care for the management
of oral mucositis in cancer patients. Support Care Cancer 2013 (31); 3165-3177.
Program Prior Authorization/Medical Necessity- Devices
Change Control
4/2019 New program.
7/2019 Aquoral added to program.
4/2020 Synerderm added to program. Added seborrheic dermatitis as an
approvable indication.
© 2024 UnitedHealthcare Services, Inc.
3
8/2020 Halucort added to program.
12/2020 Caphosol, Hyclodex and Penlen added to program.
2/2021 Hylaguard added to program.
8/2021 Alevicyn, Alevicyn Dermal Spray, Alevicyn SG, Atopiclair, Atrapro
Antipruritic Hydrogel, Atrapro CP, Atrapro Dermal Spray, Carrasyn
Hydrogel, Ceracade, Ceramax, Deripixa, Dexeryl, Emulsion SB, HPR,
Iliderm, Kendall Amorphous Hydrogel, Keragel, Keragelt, Kivik,
MediHoney, Microcyn, Phlag, PR Cream, Presera, Pruclair, Prumyx,
RadiaPlexRX, Strata GRT, Suvicort Vexasyn, and Zanabin added to
program.
9/2022 Hypocyn Dermal Spray added to program.
11/2023 Annual review. Updated references.
11/2024 Removed Carrasyn Hydrogel as it is off the market. Increased initial
authorization to 12 months.
© 2024 UnitedHealthcare Services, Inc.
4